Table 1 Clinical data of children with status asthmaticus admitted to PICU
From: Outcome of children with life-threatening asthma necessitating pediatric intensive care
Case | Total (n = 30) | Ventilated (n = 6) | Non-ventilated (n = 24) | P* |
|---|---|---|---|---|
Male (%) | 13 (0) | 5 (75) | 8 (40) | 0.06 |
Median age (IQR), yr | 3.1 (2.0-5.4) | 3.3 (2.0-5.5) | 3.1 (1.9-6.8) | 0.84 |
Median (IQR) PIM2, % | 0.50 (0.30-1.00) | 1.65 (1.45-1.95) | 0.4 (0.3-0.5) | < 0.001 |
Relevant risk factors | Â | Â | Â | Â |
Family history of atopy | 12 | 1 | 11 | 0.36 |
Prematurity < 36 weeks (%) | 4 (14) | 0 (12) | 4 (15) | 0.57 |
History of chronic lung disease, bronchiolitis, pneumonia, or pneumothorax (%) | 7 (17) | 0 (0) | 7 (25) | 0.29 |
Neurodevelopmental delay (mental retardation, cerebral palsy, neuromuscular disease) (%) | 2 (14) | 0 (25) | 2 (10) | 1.00 |
Previous asthma admission (%) | 16 (50) | 4 (62) | 12 (45) | 0.66 |
Maintenance inhaled CS (%) | 12 (35) | 3 (37) | 9 (35) | 0.66 |
Non-compliance (%) | 7 (25) | 2 (25) | 5 (25) | 0.60 |
1st PaCO2 in PICU, kPa | 5.5 (4.3-7.9) | 9.3 (6.4-10.9) | 5.1 (4.3-5.9) | 0.01 |
1st PaO2 in PICU, kPa | 9.9 (7.8-13.2) | 10.1 (9.4-13.5) | 9.3 (7.5-13.3) | 0.40 |
Viral isolation (%) | 2 (3) | 0 (0) | 2 (5) | 1.00 |
Treatment at PICU | Â | Â | Â | Â |
Systemic CS (%) | 30 (100) | 6 (100) | 24 (100) | N/A |
Inhaled salbutamol (%) | 22 (73) | 5 (83) | 17 (71) | 1.00 |
Inhaled ipratropium (%) | 7 (23) | 0 (0) | 7 (29) | 0.29 |
Inhaled adrenaline (%) | 2 (7) | 1 (17) | 1 (4) | 0.37 |
Intravenous salbutamol (%) | 22 (73) | 5 (83) | 17 (71) | 1.00 |
Intravenous magnesium sulphate (%) | 4 (13) | 2 (33) | 2 (8) | 0.17 |
Systemic antibiotics (%) | 19 (63) | 5 (83) | 14 (58) | 0.37 |
Outcome | Â | Â | Â | Â |
Median (IQR) PICU stay, day | 2.0 (1.0-2.5) | 2.5 (2.0-4.5) | 2.0 (1.0-2.0) | 0.03 |
Median (IQR) hospital stay, day | 5.0 (3.0-7.5) | 6.5 (3.0-20.0) | 5.0 (3.0-6.8) | 0.27 |
Pneumothorax (%) | 1 (3) | 0 (0) | 1 (4) | 1.00 |
Died in PICU | 0 | 0 | 0 | N/A |